The Associations Between Gonadal Hormones and Serum Uric Acid Levels in Men and Postmenopausal Women With Diabetes

Heng Wan†, Kun Zhang†, Yuying Wang†, Yi Chen†, Wen Zhang†, Fangzhen Xia†, Yunping Zhang†*, Ningjian Wang†* and Yingli Lu†*

†Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, *Department of Endocrinology and Metabolism, The People’s Hospital of Xiangyun, Shanghai, China

Introduction: In assessing the development of hyperuricemia in diabetic adults, the role of the sex steroid axis is underappreciated. Furthermore, dehydroepiandrosterone (DHEA) has been recommended as a nutritional supplement. However, is DHEA suitable for diabetic adults with hyperuricemia? This issue has received little attention.

Aim: The objective of this study was to investigate the associations between gonadal hormones and uric acid (UA) levels in diabetic adults, paying particular attention to the association between DHEA and UA levels.

Methods: We analyzed 4,426 participants out of 4,813 diabetic adults enrolled from seven communities in a cross-sectional survey conducted in 2018. Participants underwent several examinations, including assessments of anthropometric parameters, blood pressure, glucose, lipid profiles, UA, total testosterone (TT), estradiol (E2), the follicle-stimulating hormone (FSH), the luteinizing hormone (LH), and dehydroepiandrosterone (DHEA).

Results: Among men and compared with individuals in the first quartile, participants in the fourth quartile of TT and FSH had odds of hyperuricemia that were significantly decreased by so much as 48 and 34%, respectively (both $P < 0.05$). However, participants in the fourth quartile of DHEA had 79% increased odds of hyperuricemia ($P < 0.05$). Among postmenopausal women, participants in the fourth quartile of DHEA, TT, and LH had odds of hyperuricemia that were significantly increased by 155, 99, and 76%, respectively (all $P < 0.05$). These associations were adjusted for potential confounding factors.

Conclusions: Sex differences were found in the associations between gonadal hormones and UA levels in diabetic men and postmenopausal women, which should be monitored to prevent hyperuricemia when sex hormone treatment, especially DHEA, is administered. Further studies are needed.

Keywords: uric acid, hyperuricemia, gonadal hormones, dehydroepiandrosterone, estradiol, testosterone
INTRODUCTION

Uric acid (UA) is the end product of purine metabolism in humans. In the past few decades, the prevalence of hyperuricemia has rapidly increased worldwide. A recent epidemiological survey reported that the age-adjusted prevalence of hyperuricemia was 8.02% in a total sample (6.87% in women and 8.57% in men) in China (1). A large number of observational studies have demonstrated that elevations in UA levels are independently associated with not only gout and urolithiasis (2), but also hypertension, type 2 diabetes mellitus (T2DM), metabolic syndrome, endothelial dysfunction, and all-cause mortality (3–6). On the basis of this evidence, studies have reported that hyperuricemia increases the risk of diabetic complications and all-cause mortality in diabetic adults (7, 8). Therefore, for the prevention of diabetic complications and mortality, it is important to explore the prevalence of hyperuricemia and its potential risk factors.

Gonadal hormone levels are linked to age and may have different impacts on the development of metabolic diseases in men and women (9). Although epidemiologic research has shown a steady growth of hyperuricemia with increasing age in all populations (10), in elderly men and postmenopausal women, the prevalence of hyperuricemia is different, which indicates that gonadal hormones may play a role. Our previous study, referred to as the Survey on Prevalence in East China for Metabolic Disease and Risk Factors (SPECT-China), reported that higher UA levels were associated with lower total testosterone (TT) and sex hormone-binding globulin (SHBG) levels in a total of 1,365 general men (age 55.5 ± 10.8 years) (11). However, as gonadal hormone levels are quite different between individuals with and without diabetes (12), it is vital to investigate the associations between UA levels and gonadal hormone levels among individuals with diabetes. One recent study showed that, among diabetic men, hypogonadism is related to higher UA levels (13), but few studies have simultaneously analyzed the associations between gonadal hormones and UA in men and postmenopausal women with diabetes.

In addition, dehydroepiandrosterone (DHEA) has been recommended as a nutritional supplement because of its protective effects on metabolism, such as its anti-diabetes, anti-obesity and anti-atherosclerosis effects (14). Further studies have indicated that a higher prevalence of diabetic complications was associated with lower DHEA (15, 16). The vascular protective effects of DHEA may result from the nitric oxide released from intact vascular endothelial cells being acutely physiologically increased by DHEA concentrations (17). Thus, an increasing number of people with diabetes are taking DHEA to prevent diabetic complications. However, little attention has been paid to the question of whether it is suitable for diabetic adults with hyperuricemia.

Thus, in this study of a large community-based sample, we aimed to analyze the relationship between UA levels and endogenous gonadal hormone levels, including DHEA, TT, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2), in men and postmenopausal women with diabetes; we especially focused on the association between UA and DHEA levels, highlighting the importance of using gonadal hormones as important biochemical markers in both clinical and basic studies on sex-specific mechanisms of hyperuricemia. Our findings may provide evidence for the prevention and treatment of hyperuricemia in patients with diabetes.

METHODS

Study Design and Participants

We designed a cross-sectional study called the Environmental Pollutant Exposure and Metabolic Diseases in Shanghai (METAL study, www.chictr.org.cn, ChiCTR1800017573) to investigate the association between gonadal hormones and UA levels in Chinese adults with diabetes. The participants were enrolled from seven communities in Huangpu and Pudong District, Shanghai, China. Chinese citizens ≥ 18 years old who had lived in their current area for ≥ 6 months were included. Postmenopausal women were defined as subjects who reported that they had stopped menstruating for a minimum of 12 months and who were 55 years of age or older or those who had previous hysterectomy or oophorectomy; FSH ≥ 25.0 IU/L was required for all menopause criteria (according to the 2011 Stages of Gonadal Aging Workshop +10 recommendation, late perimenopausal state is characterized as FSH level ≥ 25 IU/L) (18). In August 2018, 4,813 subjects underwent an examination. We excluded participants who were missing laboratory results for UA and gonadal hormones, including TT, E2, LH, FSH, and DHEA (n = 57); who were premenopausal (n = 10); who had a history of urologic neoplasms or other cancer (n = 117); who were on treatment with the anti-thyroid gland medicine (n = 18) or thyroid hormones (n = 108), on sex hormones or steroid replacement therapy (n = 22) and who used diuretics or fibrates (n = 55) in the past week. Finally, 4,426 participants with diabetes were involved in the final analyses (Figure 1).

Measurements

A questionnaire about sociodemographic characteristics, medical history, family history, and lifestyle factors, including smoking, alcohol consumption, and dietary habits, was administered during the interview, as in previous studies (19, 20). The same group of trained and experienced personnel from the SPECT-China study (21) conducted the interviews and clinical examinations, including inspections of weight, height, and blood pressure, according to a standard protocol. Current smoking was defined as having smoked at least 100 cigarettes in one’s lifetime and currently smoking cigarettes (22). People who consumed alcohol at least once per day for at least 6 months continuously were defined as current alcohol consumers (23).

Abbreviations: UA, Uric acid; HU, hyperuricemia; T2DM, Type 2 diabetes mellitus; TT, Total testosterone; E2, Estradiol; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone; DHEA, Dehydroepiandrosterone; SHBG, sex hormone-binding globulin; FPG, Fasting plasma glucose; TG, Triglyceride; TC, Total cholesterol; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1c, Glycated hemoglobin; eGFR, Estimated glomerular filtration rate; BMI, Body mass index; OR, Odds ratio; CI, Confidence interval; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; and SGLT2, sodium-glucose cotransporter-2.
Blood samples were obtained between 6:00 and 9:00 a.m. after the participants fasted for at least 8 h. Blood was refrigerated immediately after phlebotomy, centrifuged within 2 h, and the serum was then aliquoted and frozen in a central laboratory.

TT, E2, FSH, and LH were measured by electrochemiluminescence immunoassay (Roche Cobas E601, Basel, Switzerland). DHEA and insulin were detected using the chemiluminescence method (Abbott i2000 SR, Chicago, USA). The minimal detectable limit for each gonadal hormone was as follows: 0.087 nmol/L (TT), 18.4 pmol/L (E2), 0.1 IU/L (FSH and LH), and 3.0 pg/mL (DHEA). UA, fasting plasma glucose (FPG), serum creatinine, triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured with a Beckman Coulter AU 680 (Brea, USA). Glycated hemoglobin (HbA1c) was measured by high-performance liquid chromatography (MQ-2000PT, Medconn, Shanghai, China). Samples with values below the minimal detectable limit were assigned a value midway between zero and the minimal detectable limit for the analyses (24). The interassay and intra-assay coefficients of variation were 8.33 and 6.25%, respectively, for TT, E2, FSH, and LH and 4.21 and 1.89%, respectively, for DHEA.

Hyperuricemia was defined as UA > 420 µmol/L (7 mg/dl) in both men and postmenopausal women (25). The presence of diabetes was determined when a previous diagnosis had been made by a healthcare professional, when FPG was ≥7.0 mmol/L, or when HbA1c was ≥6.5% according to the American Diabetes Association (26). Hypertension was indicated by systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or self-reported previous diagnosis of hypertension by a physician. Dyslipidemia was defined as TC ≥6.22 mmol/L (240 mg/dL), TG ≥2.26 mmol/L (200 mg/dL), LDL ≥4.14 mmol/L (160 mg/dL), HDL <1.04 mmol/L (40 mg/dL), or a self-reported previous diagnosis of hyperlipidemia by a physician according to the modified National Cholesterol Education Program-Adult Treatment Panel III. The estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation for “Asian origin” (27).

Weight (kilograms) and height (centimeters) were measured using a stadiometer and a vertical ruler while subjects wore light clothing without shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
Statistical Analysis
Data analyses were performed using IBM SPSS Statistics, Version 22 (IBM Corporation, Armonk, NY, USA). A \( P < 0.05 \) indicated significance (two sided). Continuous variables are summarized as the mean \( \pm \) SD or median (interquartile range), and categorical variables are summarized as percentages (%). Continuous variables were compared using Student's \( t \)-test. The Mann-Whitney U test was used for non-normally distributed continuous variables, and the Pearson \( \chi^2 \) test was used for dichotomous variables. Linear or logistic regression analysis was used to test for trends in the variable changes across the DHEA and TT quartiles, providing unadjusted \( P \)-values for trends.

The associations between serum UA and gonadal hormone level quartiles in adults with diabetes were assessed by multiple linear regression. Data are expressed as unstandardized coefficients (\( \beta \)) (95% confidence intervals). The model was adjusted for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HbA1c, eGFR (including age), and the usage of aspirin, losartan, and irbesartan.

The subjects were subsequently divided into normal and hyperuricemia groups. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression to determine the risk of hyperuricemia for each quartile of reproductive hormone levels by using the first quartile as the reference. The same model was adjusted separately.

Sensitivity analyses were performed. We conducted further subgroup analysis based on the subjects with or without hyperuricemia. We also calculated the associations between gonadal hormones and UA level in adults with diabetes after excluding \( \pm 3 \) SD values of UA levels by multiple linear regression. The same model was adjusted. In addition, to investigate whether the treatment for diabetes affects the association, we analyzed the associations between UA level or prevalence of hyperuricemia and gonadal hormone level quartiles after adjusting for the model, including alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HbA1c, eGFR, the usage of aspirin, losartan, and irbesartan, and the usage of metformin, sulfonylurea or glinides, alpha-glucosidase inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin. A \( P \)-value (two sided) < 0.05 indicated significance.

RESULTS
Characteristics of Participants With and Without Hyperuricemia
The characteristics of the study subjects with and without hyperuricemia are summarized in Table 1. A total of 4,426 subjects (2,164 men and 2,262 postmenopausal women) were involved in the final analyses. The mean age of the study population was 67.44 \( \pm \) 8.77 years among men and 67.79 \( \pm \) 7.75 years among postmenopausal women. The prevalence of hyperuricemia, hypertension, and dyslipidemia was 13.2% (16.9% in men and 9.8% in postmenopausal women), 78.8% (78.1% in men and 79.5% in postmenopausal women), and 61.9% (63.5% in men and 60.3% in postmenopausal women), respectively. Compared to those without hyperuricemia [HU (–)], men with hyperuricemia [HU (+)] had a significantly longer duration of diabetes; greater BMI; lower levels of FPG, HbA1c, HDL, eGFR, and TT; higher levels of TG and DHEA; and a higher prevalence of hypertension and dyslipidemia (\( P < 0.05 \)). Compared to those without hyperuricemia [HU (–)], postmenopausal women with hyperuricemia [HU (+)] were older and had a significantly greater BMI; lower levels of HDL and eGFR; higher levels of TG, TT, FSH, LH, and DHEA; and a higher prevalence of hypertension and dyslipidemia (\( P < 0.05 \)).

Metabolic Characteristics of Subjects by DHEA and TT Quartiles
The metabolic characteristics of subjects grouped by DHEA-level quartiles are shown in Table 2. Compared with the men in the lowest DHEA quartile, men in the highest quartile were younger, had a shorter duration of diabetes, had greater UA and eGFR levels, and had a higher prevalence of dyslipidemia (all \( P \) for trend < 0.05). Compared with the postmenopausal women in the lowest DHEA quartile, postmenopausal women in the highest quartile were younger, had a shorter duration of diabetes and had higher FPG, UA, and eGFR (all \( P \) for trend < 0.05). Supplementary Table 1 shows the metabolic characteristics of subjects grouped by TT level quartiles.

Associations Between Gonadal Hormones and UA Levels
Table 3 shows the associations between gonadal hormones and UA levels in adults with diabetes. Compared with men in the first quartile, after adjusting for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HbA1c, eGFR, and the usage of aspirin, losartan, and irbesartan, men in the fourth quartile of TT and FSH had lower UA levels \([ (\beta = −22.67, 95\% \ CI = −35.29, and −12.75) and (\beta = −14.79, 95\% \ CI = −24.41, and −5.17), respectively] (both \( P < 0.05 \)). The UA level also decreased with the increased TT and FSH quartiles (\( P \) for trend < 0.05). However, compared with men in the first quartile of DHEA, men in the fourth quartile had higher UA levels after adjusting for the same variables \((\beta = 23.27, 95\% \ CI = 13.93, and 32.62) (P < 0.05). The UA level also increased significantly with increasing DHEA quartiles (\( P \) for trend < 0.05). No significant associations between E2, LH, and UA levels were found among men. Among the postmenopausal women, after adjusting for the same variables, compared with the first quartile, individuals in the fourth quartile of DHEA, TT, and LH had higher UA levels \([ (\beta = 34.70, 95\% \ CI = 26.26, and 43.15), (\beta = 19.49, 95\% \ CI = 10.80, and 28.19) and (\beta = 10.77, 95\% \ CI = 1.88, and 19.67), respectively] (all \( P < 0.05 \)). The UA level also increased significantly with the increased DHEA, TT, and LH quartiles (all \( P \) for trend <0.05), and no significant associations were found between E2, FSH, and UA among postmenopausal women.
**TABLE 1** | General characteristics of subjects with and without hyperuricemia (HU).

| Characteristic          | Men                  | Postmenopausal women |
|-------------------------|----------------------|----------------------|
|                        | HU (−)               | HU (+)               | P Value | HU (−)   | HU (+)   | P Value |
| N                       | 1,798                | 366                  | −       | 2,041    | 221      | −       |
| Age, year               | 67.48 ± 8.49         | 67.22 ± 10.04        | 0.635   | 67.49 ± 7.61 | 70.45 ± 8.51 | <0.001 |
| Duration of diabetes, year | 10 (4.15)           | 8 (3.15)             | 0.038   | 9 (3.15)  | 10 (3.16.5) | 0.563   |
| Current smoking, %      | 36.8                 | 33.8                 | 0.309   | 2.5       | 2.3       | 0.844   |
| Current alcohol use, %  | 39.4                 | 42.1                 | 0.347   | 5.7       | 3.2       | 0.122   |
| BMI, kg/m²              | 24.85 ± 3.30         | 25.88 ± 3.30         | <0.001  | 24.60 ± 3.63 | 26.75 ± 4.20 | <0.001 |
| FPG, mmol/L             | 7.96 ± 2.41          | 7.29 ± 1.96          | <0.001  | 7.74 ± 2.44 | 7.69 ± 2.32 | 0.782   |
| HDa1c, %                | 7.67 ± 1.46          | 7.17 ± 1.09          | <0.001  | 7.41 ± 1.35 | 7.34 ± 1.22 | 0.450   |
| TC, mmol/L              | 4.80 ± 1.08          | 4.88 ± 1.26          | 0.259   | 5.37 ± 1.21 | 5.45 ± 1.34 | 0.373   |
| TG, mmol/L              | 1.38 (1.01, 1.99)    | 1.73 (1.26, 2.52)    | <0.001  | 1.56 (1.13, 2.20) | 2.00 (1.44, 2.99) | <0.001 |
| HDL, mmol/L             | 1.12 ± 0.26          | 1.06 ± 0.23          | <0.001  | 1.31 ± 0.30 | 1.17 ± 0.25 | <0.001  |
| LDL, mmol/L             | 2.99 ± 0.79          | 3.01±0.81            | 0.764   | 3.29±0.87  | 3.33±0.90  | 0.538   |
| UA, µmol/L              | 318.10±58.34         | 473.62±54.25         | <0.001  | 294.67±60.96 | 465.77±47.22 | <0.001  |
| Hypertension, %         | 76.9                 | 83.9                 | 0.003   | 78.5      | 89.1      | <0.001  |
| Dystipidemia, %         | 61.6                 | 73.0                 | <0.001  | 58.6      | 76.9      | <0.001  |
| eGFR, ml/min per 1.73 m²| 92.27 ± 15.84        | 81.33 ± 20.53        | <0.001  | 93.74 ± 14.94 | 75.61 ± 21.81 | <0.001  |
| TT, mmol/L              | 14.28 (11.03, 18.37) | 12.93 (9.74, 16.57) | <0.001  | 0.53 (0.29, 0.81) | 0.60 (0.40, 0.99) | <0.001  |
| E2, pmol/L              | 116.10 (91.57, 139.90) | 121.75 (93.87, 145.85) | 0.091   | 39.74 (9.18, 59.91) | 37.76 (9.18, 50.67) | 0.072 |
| FSH, IU/L               | 9.57 (8.52, 14.39)   | 9.34 (5.88, 13.93)   | 0.867   | 53.25 (39.98, 68.42) | 54.46 (40.41, 74.03) | 0.007 |
| LH, IU/L                | 7.21 (5.30, 9.87)    | 7.32 (5.34, 10.12)   | 0.829   | 24.69 (18.20, 31.67) | 27.96 (21.23, 36.22) | <0.001 |
| DHEA, pg/mL             | 171.35 (118.98, 236.40) | 180.35 (119.90, 262.93) | 0.011   | 117.10 (78.40, 162.95) | 126.70 (86.90, 187.55) | 0.006 |

**Medicine use**

| Losartan and irbesartan, % | 7.1 | 10.2 | 0.042 | 6.7 | 10.6 | 0.034 |
| Aspirin, %                | 6.7 | 7.9  | 0.367 | 3.7 | 5.0  | 0.357 |

The data are summarized as the mean ± SD or median (interquartile range) for continuous variables or as a numerical proportion for categorical variables. P-values were calculated by Student’s t-test, the Mann–Whitney U-test, or Pearson’s χ² test. P-values <0.05 were considered significantly different. HU, hyperuricemia; BMI, body mass index; FPG, fasting plasma glucose; HDa1c, glycated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UA, uric acid; eGFR, glomerular filtration rate; TT, total testosterone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; DHEA, dehydroepiandrosterone.

**Associations Between Gonadal Hormone Levels and the Prevalence of Hyperuricemia**

The results of the associations between gonadal hormone levels and the prevalence of hyperuricemia in adults with diabetes are shown in Table 4. Among men, after adjusting for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HDa1c, eGFR, and the usage of aspirin, losartan, and irbesartan, compared with the first quartile, participants in the fourth quartile of TT and FSH had odds of hyperuricemia that were significantly decreased by 48% (OR 0.52, 95% CI 0.35, and 0.77) and 34% (OR 0.66, 95% CI 0.45, and 0.95) (both P < 0.05). However, participants in the fourth quartile of DHEA had odds of hyperuricemia that were significantly increased by 33% (OR 1.76, 95% CI 1.05, and 2.94), respectively (all P < 0.05). No associations were found between E2 and FSH and the prevalence of hyperuricemia.

**Sensitivity Analyses**

Among diabetic men without hyperuricemia, DHEA (positively) and TT (negatively) were still associated with UA levels; however, FSH was not significantly associated with UA levels. Among diabetic postmenopausal women without hyperuricemia, DHEA, and TT were still positively associated with UA levels; however, LH was not significantly associated with UA levels (Supplementary Table 2). Among diabetic men and postmenopausal women with hyperuricemia, no significant association was found between gonadal hormones (including DHEA, TT, LH, FSH, and E2) and UA levels (Supplementary Table 3). These associations were all adjusted for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HDa1c, eGFR, and the usage of aspirin, losartan, and irbesartan. The differences between the participants with and without hyperuricemia may be account for
the number of the participants with hyperuricemia was too small.

To eliminate the effects of extreme uric acid levels on the results, we calculated the associations between gonadal hormones and UA levels after excluding ± 3 SD values of UA. Fifteen men and 12 postmenopausal women were excluded. The associations of TT and DHEA with UA levels in men and postmenopausal women remained consistent (Supplementary Table 4).

Among men, the percentage of participants taking metformin, sulfonylurea or glinides, alpha-glucosidase inhibitor, DPP-4 inhibitor, GLP-1 analogs, thiazolidinediones, SGLT2-inhibitor, and insulin was 41.1, 42.3, 27.7, 2.4, 0.1, 3.8, 0.1, and 19.0%, respectively. The percentage of participants without taking antidiabetic drugs was 8.3%. Among postmenopausal women, the percentage of participants taking metformin, sulfonylurea or glinides, alpha-glucosidase inhibitor, DPP-4 inhibitor, GLP-1 analogs, thiazolidinediones, SGLT2-inhibitor, and insulin was 42.8, 43.9, 27.9, 2.6, 0.1, 4.0, 0.1, and 16.2%, respectively. The percentage of participants without taking antidiabetic drugs was 9.5%. After adjusting for the further model including the usage of antidiabetic medicine, the associations between gonadal hormones quartiles and UA level (Supplementary Table 5) and the associations between gonadal hormone quartiles and the prevalence of hyperuricemia (Supplementary Table 6) remained as consistent as before.

### TABLE 2 | Metabolic characteristics of subjects by DHEA quartiles.

| Characteristic | DHEA, pg/mL | P for trend |
|---------------|-------------|-------------|
|               | Q1          | Q2          | Q3          | Q4          |           |
| Men           |             |             |             |             |           |
| DHEA, pg/mL   | ≤119.15     | 119.16–172.85 | 172.88–240.70 | >240.70     | –         |
| N             | 541         | 541         | 542         | 540         | –         |
| Age, yr       | 71.84 ± 8.51 | 68.29 ± 7.69 | 66.36 ± 7.86 | 63.26 ± 8.73 | <0.001    |
| Duration of diabetes, yr | 10 (4,18) | 8 (4,15) | 10 (3,15) | 8 (3,15) | 0.001 |
| BMI, kg/m²    | 25.14 ± 3.27 | 24.77 ± 3.23 | 24.94 ± 3.33 | 25.23 ± 3.44 | 0.505 |
| FPG, mmol/L   | 7.76 ± 2.30 | 7.81 ± 2.33 | 7.89 ± 2.44 | 7.93 ± 2.33 | 0.195 |
| HbA1c, %      | 7.62 ± 1.41 | 7.54 ± 1.39 | 7.64 ± 1.48 | 7.53 ± 1.38 | 0.558 |
| TC, mmol/L    | 4.77 ± 1.19 | 4.80 ± 1.16 | 4.80 ± 1.02 | 4.89 ± 1.07 | 0.079 |
| TG, mmol/L    | 1.44 (1.07, 1.99) | 1.39 (1.03, 2.08) | 1.40 (1.02, 2.03) | 1.52 (1.06, 2.21) | 0.353 |
| HDL, mmol/L   | 1.09 ± 0.25 | 1.10 ± 0.25 | 1.12 ± 0.26 | 1.12 ± 0.25 | 0.090 |
| LDL, mmol/L   | 2.98 ± 0.84 | 2.98 ± 0.82 | 3.00 ± 0.75 | 3.04 ± 0.75 | 0.171 |
| UA, µmol/L    | 344.60 ± 87.02 | 337.71 ± 76.60 | 336.96 ± 82.11 | 358.36 ± 80.37 | 0.010 |
| Hypertension, %| 78.7 | 78.6 | 76.4 | 78.5 | 0.720 |
| Dyslipidemia, %| 67.7 | 66.0 | 60.3 | 60.2 | 0.002 |
| eGFR, ml/min per 1.73 m² | 86.62 ± 17.42 | 88.93 ± 16.90 | 92.32 ± 16.17 | 93.81 ± 17.50 | <0.001 |

### Postmenopausal women

| Characteristic | DHEA, pg/mL | P for trend |
|---------------|-------------|-------------|
|               |             |             |             |             |           |
| DHEA, pg/mL   | ≤79.20      | 79.03–118.05 | 118.06–164.40 | >164.40     | –         |
| N             | 567         | 564         | 567         | 564         | –         |
| Age, yr       | 69.84 ± 7.66 | 68.41± 7.39 | 66.89± 7.53 | 65.98± 7.85 | <0.001 |
| Duration of diabetes, yr | 9 (3,15) | 10 (4,18) | 8 (3,15) | 8 (3,15) | 0.133 |
| BMI, kg/m²    | 24.73 ± 3.75 | 24.68 ± 3.74 | 24.94 ± 3.74 | 24.89 ± 3.75 | 0.300 |
| FPG, mmol/L   | 7.51 ± 2.23 | 7.79 ± 2.60 | 7.67 ± 2.43 | 7.95 ± 2.42 | 0.009 |
| HbA1c, %      | 7.40 ± 1.29 | 7.42 ± 1.40 | 7.38 ± 1.26 | 7.44 ± 1.38 | 0.190 |
| TC, mmol/L    | 5.28 ± 1.19 | 5.38 ± 1.20 | 5.42 ± 1.26 | 5.42 ± 1.21 | 0.065 |
| TG, mmol/L    | 1.58 (1.14, 2.24) | 1.63 (1.16, 2.31) | 1.58 (1.17, 2.16) | 1.64 (1.13, 2.30) | 0.357 |
| HDL, mmol/L   | 1.30 ± 0.29 | 1.27 ± 0.30 | 1.30 ± 0.31 | 1.30 ± 0.30 | 0.571 |
| LDL, mmol/L   | 3.23 ± 0.88 | 3.31 ± 0.85 | 3.32 ± 0.92 | 3.33 ± 0.85 | 0.055 |
| UA, µmol/L    | 297.70 ± 77.70 | 307.79 ± 79.41 | 314.28 ± 76.33 | 325.84 ± 77.81 | <0.001 |
| Hypertension, %| 80.8 | 78.0 | 79.0 | 80.5 | 0.968 |
| Dyslipidemia, %| 60.8 | 60.6 | 58.7 | 61.3 | 0.964 |
| eGFR, ml/min per 1.73 m² | 89.74 ± 17.48 | 92.15 ± 15.36 | 92.13 ± 15.67 | 93.86 ± 16.27 | <0.001 |

The data are summarized as the mean ± SD or median (interquartile range) for continuous variables or as a numerical proportion for categorical variables. P for trend was calculated by regression tests. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UA, uric acid; eGFR, glomerular filtration rate; DHEA, dehydroepiandrosterone.
### TABLE 3 | Associations between gonadal hormones quartiles and UA level.

|                  | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | 1 SD increment in gonadal hormone |
|------------------|------------|------------|------------|------------|-------------|-----------------------------------|
| **Men**          |            |            |            |            |             |                                   |
| DHEA             | Ref.       | −3.65 (−12.86, 5.57) | −1.37 (−10.69, 7.95) | 23.27 (13.93, 32.62) | <0.001 | 11.40 (8.09, 14.72) |
| TT               | Ref.       | −10.92 (−20.23, −1.60) | −8.26 (−17.75, 1.23) | −22.67 (−32.59, −12.75) | <0.001 | −8.10 (−11.60, −4.60) |
| E2               | Ref.       | −8.14 (−17.48, 1.20) | −7.02 (−16.40, 2.37) | −3.48 (−12.91, 5.95) | 0.543 | −1.56 (−5.05, 1.93) |
| LH               | Ref.       | −4.89 (−14.33, 4.58) | −5.11 (−14.63, 4.42) | −7.89 (−17.72, 1.95) | 0.133 | −5.45 (−9.04, −1.87) |
| FSH              | Ref.       | −9.37 (−18.74, 0.01) | −11.28 (−20.77, −1.78) | −14.79 (−24.41, −5.17) | 0.003 | −5.34 (−8.81, −1.88) |

**Postmenopausal women**

|                  | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | 1 SD increment in gonadal hormone |
|------------------|------------|------------|------------|------------|-------------|-----------------------------------|
| DHEA             | Ref.       | 14.63 (6.23, 23.04) | 19.10 (10.62, 27.58) | 34.70 (26.26, 43.15) | <0.001 | 11.29 (8.32, 14.26) |
| TT               | Ref.       | 12.16 (3.72, 20.61) | 11.57 (2.97, 20.17) | 19.49 (10.80, 28.19) | <0.001 | 5.94 (2.89, 8.99) |
| E2               | Ref.       | 7.18 (−2.46, 16.82) | 2.52 (−5.28, 10.34) | −2.20 (−10.27, 5.87) | 0.673 | −0.05 (−3.18, 3.07) |
| LH               | Ref.       | −0.88 (−9.40, 7.65) | −0.49 (−8.98, 8.00) | 10.77 (1.88, 19.67) | 0.030 | 5.60 (2.33, 8.86) |
| FSH              | Ref.       | −0.37 (−8.94, 8.20) | −6.50 (−15.23, 2.23) | −1.57 (−10.69, 7.55) | 0.444 | −0.14 (−3.41, 3.13) |

Data are expressed as odds ratios (95% CIs). Logistic regression analysis was used. Each gonadal hormone was separately adjusted for confounding factors. The model was adjusted for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HbA1c, eGFR (including age), and the usage of aspirin, losartan, and irbesartan. UA, uric acid; BMI, body mass index; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; TT, total testosterone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; DHEA, dehydroepiandrosterone.

### TABLE 4 | Associations between gonadal hormone quartiles and the prevalence of HU.

|                  | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | 1 SD increment in gonadal hormone |
|------------------|------------|------------|------------|------------|-------------|-----------------------------------|
| **Men**          |            |            |            |            |             |                                   |
| DHEA             | Ref.       | 0.82 (0.57, 1.19) | 0.87 (0.59, 1.28) | 1.79 (1.26, 2.53) | 0.001 | 1.29 (1.14, 1.46) |
| TT               | Ref.       | 0.64 (0.45, 0.91) | 0.72 (0.51, 1.03) | 0.52 (0.35, 0.77) | 0.003 | 0.79 (0.68, 0.92) |
| E2               | Ref.       | 0.96 (0.66, 1.40) | 1.00 (0.69, 1.45) | 1.34 (0.94, 1.92) | 0.097 | 1.07 (0.94, 1.20) |
| LH               | Ref.       | 1.08 (0.75, 1.56) | 0.88 (0.61, 1.28) | 0.93 (0.63, 1.36) | 0.497 | 0.93 (0.80, 1.07) |
| FSH              | Ref.       | 0.66 (0.46, 0.95) | 0.77 (0.54, 1.20) | 0.66 (0.45, 0.95) | 0.058 | 0.94 (0.82, 1.07) |

**Postmenopausal women**

|                  | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | 1 SD increment in gonadal hormone |
|------------------|------------|------------|------------|------------|-------------|-----------------------------------|
| DHEA             | Ref.       | 1.49 (0.90, 2.48) | 1.25 (0.74, 2.12) | 2.55 (1.58, 4.13) | <0.001 | 1.34 (1.15, 1.56) |
| TT               | Ref.       | 2.00 (1.19, 3.37) | 1.62 (0.94, 2.80) | 1.99 (1.18, 3.33) | 0.043 | 1.17 (1.01, 1.36) |
| E2               | Ref.       | 1.44 (0.84, 2.48) | 1.40 (0.89, 2.18) | 1.09 (0.70, 1.71) | 0.630 | 1.00 (0.84, 1.18) |
| LH               | Ref.       | 1.39 (0.83, 2.34) | 1.26 (0.75, 2.11) | 1.76 (1.05, 2.94) | 0.051 | 1.22 (1.04, 1.44) |
| FSH              | Ref.       | 1.26 (0.78, 2.04) | 0.82 (0.49, 1.37) | 1.05 (0.63, 1.74) | 0.729 | 1.08 (0.91, 1.28) |

Data are expressed as odds ratios (95% CIs). Logistic regression analysis was used. Each gonadal hormone was separately adjusted for confounding factors. The model was adjusted for alcohol consumption status, smoking status, duration of diabetes, hypertension, dyslipidemia, BMI, HbA1c, eGFR (including age), and the usage of aspirin, losartan, and irbesartan. HU, hyperuricemia; BMI, body mass index; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; TT, total testosterone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; DHEA, dehydroepiandrosterone.

### DISCUSSION

In this study, among over 4,000 community-dwelling Chinese adults, we reported that DHEA (positively), TT (negatively), and FSH (negatively) were associated with UA levels in men, and DHEA, TT, and LH were all positively associated with UA levels in postmenopausal women after adjusting for possible confounders. To the best of our knowledge, this study is the first to evaluate the associations between gonadal hormones and UA levels in a large population including men and postmenopausal women with diabetes simultaneously. The sex differences in the association between gonadal hormones and UA levels may indicate sex-specific mechanisms of hyperuricemia and the function of UA, using gonadal hormones as biochemical markers. More importantly, our results showed that DHEA was associated with UA levels in both men and postmenopausal women with diabetes, which should draw public attention to the question of whether DHEA should be used in diabetic adults with hyperuricemia.

DHEA, a biomarker of hypothalamic-pituitary-adrenal axis activity (28), is a steroid hormone that has several effects on metabolism, such as anti-diabetes, anti-obesity, and anti-atherosclerosis effects (29, 30); DHEA has also been available as a health food supplement in the USA. However, few studies have investigated the adverse effects of DHEA. As far as we know, only one study, the participants in which were recruited from a single hospital, reported that DHEA was positively associated with UA (13). In our study, a positive and significant
association between DHEA and UA was observed in both men and postmenopausal women. We suspected that the possible mechanism is that DHEA may increase sodium reabsorption and reduce water removal, as it has been reported that DHEA could activate mineralocorticoid receptor and inhibit glucocorticoid receptor (31), which would lead to serum UA concentration increases by reduced renal UA excretion (13). However, the specific mechanism is still not clear. Further research is needed to clarify the correlation and mechanism between DHEA and UA.

In the present study, gonadal hormone levels were differently associated with UA levels between men and postmenopausal women. The UA level increased with decreasing testosterone levels in men; however, the UA level increased with increasing testosterone levels in postmenopausal women. A previous study found an inverse association between testosterone levels and UA levels among men with and without T2DM separately (11, 13). These results are consistent with our findings. However, in postmenopausal women, testosterone administration was reported to cause a definite increase in plasma UA levels (32). Furthermore, some reports have shown that testosterone treatment for female to male gender reassignment leads to increased serum UA concentrations (33, 34). These findings are similar to ours. As few studies have reported the relationship between endogenous testosterone and UA in postmenopausal women, our study may supplement the knowledge on this relationship.

The association between E2 and UA is controversial. Although postmenopausal status has been recognized as a significant determinant of higher serum UA concentrations in women in the general population (35), Krishnan considered that aging, not menopause, was associated with a higher prevalence of hyperuricemia among older women (36). However, a reduction in serum UA has been observed after accepting hormone replacement therapy in postmenopausal women with hyperuricemia (37). Interestingly, Jung, J. H. evaluated the effects of different types of hormone therapy on serum UA levels and attributed the findings to the effects of progestogen, rather than E2 (38), which is similar to the result of our study showing that E2 is not associated with UA in postmenopausal women. We also observed no association between E2 and UA in men, which is consistent with the results of a previous study (13).

The associations between FSH, LH, and UA levels are controversial. One previous study reported that both men and women with gout had lower FSH and LH levels (39). Two other studies have shown that LH and FSH decreased with elevated UA levels in men (11, 13). We also observed that FSH was negatively associated with UA among men with diabetes and that LH had a positive association with UA among postmenopausal women with diabetes. The different results may be caused by factors associated with the different populations. Further studies are needed to reveal this relationship.

Although our study had some strengths, including novelty, the inclusion of a relatively large sample of community-dwelling participants and strong quality control, there were also some limitations. First, this is a cross-sectional study; thus, causal relationships between gonadal hormones and UA cannot be confirmed. Second, the participants in this study were all diabetic adults; thus, the results may not be generalizable to the entire population. Third, we did not measure the SHBG and free testosterone levels in the present study while considering the cost, which may limit the investigation on the relationship between testosterone and UA in patients with diabetes. Further cohort or randomized controlled studies with larger sample sizes are still required.

**CONCLUSIONS**

DHEA (positively), TT (negatively), and FSH (negatively) were associated with UA levels among men with diabetes, and DHEA, TT, and LH were all positively associated with UA levels in postmenopausal women with diabetes after adjusting for possible confounders. This may provide a new clinical understanding and assist in the treatment of hyperuricemia in diabetic patients. Furthermore, our findings suggest that the level of UA be monitored to prevent hyperuricemia when DHEA is administered in diabetic adults, although the definite effect and potential pathogenic effect of DHEA on UA levels both need further investigation.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

**ETHICS STATEMENT**

The study protocol was approved by the Ethics Committee of Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the appropriate institutional review committee. Written informed consent was obtained from all participants included in the study.

**AUTHOR CONTRIBUTIONS**

YL and NW designed the study. HW, YW, YC, WZ, and FX conducted the research. HW, KZ, and YZ analyzed the data. HW wrote the manuscript. The final manuscript was read and approved by all authors.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (91857117, 81600614); the Science and Technology Commission of Shanghai Municipality (19140902400, 18410722300); the Major Science and Technology Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00059); the Commission of Health and Family Planning of Pudong District (PWZxq2017-17); the Municipal Human Resources Development Program for
Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ053); and the Shanghai JiaoTong University School of Medicine (19XJ11007). The funders played no role in the design or conduction of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the article.

ACKNOWLEDGMENTS

The abstract was selected by the Annual Meeting Steering Committee for a poster presentation at ENDO 2019 in New Orleans, Louisiana (3-4). We confirm that we have permission to reuse the material. The authors thank all team members and participants in the METAL study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.00055/full#supplementary-material

REFERENCES

1. Cui L, Meng L, Wang G, Yuan X, Li Z, Mu R, et al. Prevalence and risk factors of hyperuricemia: results of the kaihuan cohort study. Mod Rheumatol. (2017) 27:1066–71. doi: 10.1080/14395795.2017.1300117
2. Abou-Elela A. Epidemiology, pathophysiology, and management of uric acid urolithiasis: a narrative review. J Adv Res. (2017) 8:513–27. doi: 10.1016/j.jare.2017.04.005
3. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. (2008) 359:1811–21. doi: 10.1056/NEJMra0800885
4. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. (2009) 32:1737–42. doi: 10.2337/dc09-0288
5. Zhan Z, Bian L, Choi Y. Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology. (2012) 63:420–8. doi: 10.1177/0003319711423806
6. Cheong E, Ryu S, Lee JY, Lee SH, Sung JW, Cho DS, et al. Association between serum uric acid and cardiovascular mortality and all-cause mortality: a cohort study. J Hypertens. (2017) 35(Suppl. 1):S3–9. doi: 10.1097/HJH.0000000000001330
7. Lamacchia O, Fontana A, Pacilli A, Copetti M, Fariello S, Garofolo M, et al. On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. Atherosclerosis. (2017) 260:20–6. doi: 10.1016/j.atherosclerosis.2017.03.008
8. Deng Z, Gu Y, Hou X, Zhang L, Bao Y, Hu C, et al. Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study. Diabetes Metab Res Rev. (2016) 32:325–32. doi: 10.1002/dmrr.2724
9. Liu S, Sun Q. Sex differences, endogenous sex-hormone, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. J Diabetes. (2018) 10:428–41. doi: 10.1111/1753-0407.12517
10. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in china. Sci Rep. (2018) 8:4314. doi: 10.1038/s41598-018-02257-9
11. Gao F, Jiang B, Cang Z, Wang N, Han B, Li Q, et al. Serum uric acid is associated with erectile dysfunction: a population-based cross-sectional study in Chinese men. Sci Rep. (2017) 7:2087. doi: 10.1038/s41598-017-02392-x
12. Zhu H, Wang N, Han B, Li Q, Chen Y, Zhu C, et al. Low sex hormone-binding globulin levels associate with prediabetes in Chinese men independent of total testosterone. PLoS ONE. (2016) 11:e0162004. doi: 10.1371/journal.pone.0162004
13. Cao W, Zheng RD, Xu SH, Fan YE, Sun HP, Liu C. Association between sex hormone and blood uric acid in male patients with type 2 diabetes. Int J Endocrinol. (2017) 2017:437523. doi: 10.1155/2017/437523
14. Tchernev A, Labrie F, Belanger A, Despres JP. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol. (1996) 150:155–64.
15. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Hasegawa G, Yoshikawa T. Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes: a possible link between urinary albumin excretion and cardiovascular disease. Diabetes Care. (2004) 27:2893–7. doi: 10.2337/diacare.27.12.2893
16. Wang C, Zhang W, Wang Y, Wan H, Chen Y, Xia F, et al. Novel associations between sex hormones and diabetic vascular complications in men and postmenopausal women: a cross-sectional study. Cardiovasc Diabetol. (2019) 18:97. doi: 10.1186/s12933-019-0901-6
17. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab. (2004) 89:4708–15. doi: 10.1210/jc.2003-031560
18. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. (2012) 97:1159–68. doi: 10.1210/jc.2011-3362
19. Wan H, Wang Y, Zhang K, Chen Y, Fang S, Zhang W, et al. Associations between vitamin d and microvascular complications in middle-aged and elderly diabetic patients. Endocr Pract. (2019) 25:809–16. doi: 10.4158/EP-2019-0015
20. Wang Y, Wan H, Chen Y, Xia F, Zhang W, Wang C, et al. Association of c-peeptide with diabetic vascular complications in type 2 diabetes. Diabetes Metab. (2019) 1262–3636:30064–3. doi: 10.1016/j.diabet.2019.04.004
21. Wang N, Chen Y, Ning Z, Li Q, Han B, Zhu C, et al. Exposure to famine in early life and nonalcoholic fatty liver disease in adulthood. J Diabetes. (2016) 10:2218–25. doi: 10.1210/jc.2016-1076
22. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. (2013) 310:948–59. doi: 10.1001/jama.2013.168118
23. Tan JR, Chen YH, Bi YE, Xu M, Huang Y, Dai M, et al. Prepyertension is associated with atherosclerosis in type 2 diabetes. J Diabetes. (2010) 2:56–63. doi: 10.1111/j.1753-0407.2009.00862.x
24. Bjornerem A, Straume B, Midtby M, Fonnebo V, Sundsfjord J, Svartberg J, et al. Serum dehydroepiandrosterone and other steroid hormone concentrations throughout adulthood. J Clin Endocrinol Metab. (2019) 63. doi: 10.1111/jcem.2019-031560
29. Aoki K, Terauchi Y. Effect of dehydroepiandrosterone (dhea) on diabetes mellitus and obesity. *Vitam Horm.* (2018) 108:355–65. doi: 10.1016/bs.vh.2018.01.008

30. Brahimaj A, Muka T, Kavousi M, Laven JS, Dehghan A, Franco OH. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the rotterdam study. *Diabetologia.* (2017) 60:98–106. doi: 10.1007/s00125-016-4136-8

31. Clark BJ, Prough RA, Klinge CM. Mechanisms of action of dehydroepiandrosterone. *Vitam Horm.* (2018) 108:29–73. doi: 10.1016/bs.vh.2018.02.003

32. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. *Acta Endocrinol.* (1977) 85:198–208. doi: 10.1530/acta.0.0850198

33. Kurahashi H, Watanabe M, Sugimoto M, Ariyoshi Y, Mahmood S, Araki M, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. *Endocr J.* (2013) 60:1321–7. doi: 10.1507/endocrj.EJ13-0203

34. Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, Morcillo S, Rojo-Martinez G, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. *J Clin Endocrinol Metab.* (2008) 93:2230–3. doi: 10.1210/jc.2007-2467

35. Mumford SL, Dasharathy SS, Pollack AZ, Perkins NJ, Mattison DR, Cole SR, et al. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the biocyte study. *Hum Reprod.* (2013) 28:1853–62. doi: 10.1093/humrep/det085

36. Krishnan E, Bennett M, Chen L. Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women. *Menopause.* (2014) 21:1211–6. doi: 10.1097/GME.0000000000000230

37. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. *Lancet.* (1999) 354:650. doi: 10.1016/S0140-6736(99)92381-4

38. Jung HJ, Song GG, Lee YH, Kim JH, Hyun MH, Choi SJ. Serum uric acid levels and hormone therapy type: a retrospective cohort study of postmenopausal women. *Menopause.* (2018) 25:77–81. doi: 10.1097/GME.0000000000000953

39. Marinello E, Riario-Sforza G, Marcolongo R. Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout. *Arthritis Rheum.* (1985) 28:127–31. doi: 10.1002/art.1780280203

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Frontiers in Endocrinology* • www.frontiersin.org 10

February 2020 | Volume 11 | Article 55

*Gonadal Hormones and Uric Acid*